Fascia Iliaca Block

3

Review clinical trials related to Fascia Iliaca Block. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture Surgery

Older patients with hip fractures often suffer from severe pain. Inadequate analgesia increases the risk of postoperative delirium, myocardial injury, and other complications. Peripheral nerve block is an important component of multimodal analgesia, but conventional local anesthetics (such as plain bupivacaine) provide only approximately 12 hours of analgesic duration, which is far from covering the most painful 72 hours after surgery. Liposomal bupivacaine has a slow-release property, prolonging the analgesic duration up to 72 hours after a single injection. However, its clinical advantages in hip fracture surgery remain controversial. The investigators suppose that, compared with plain bupivacaine alone, preoperative supra-inguinal fascia iliaca block using liposomal bupivacaine combined with plain bupivacaine can further improve analgesia, decrease opioid consumption, and improve postoperative recovery quality within 72 hours in older patients after hip fracture surgery.

Participants needed: 148
Trial details
Phase: Phase 4Age: 55+Biological sex: AllType: InterventionalSponsor: Peking University First HospitalUpdated: Jun 15, 2026Locations: 1
Eligibility criteria

Aged ≥ 55 years. [+2]

Inability to communicate due to visual, auditory, language, or other reasons bef... [+5]

Status: Recruiting

Transcatheter Aortic Valve Implantation: Comparison of the Effects of Ultrasound-Guided Pericapsular Nerve Group Block and Fascia Iliaca Block on Postoperative Analgesia Management

Aortic Stenosis (AS) is the most common valvular pathology, particularly prevalent in advanced age, and Transcatheter Aortic Valve Implantation (TAVI) has become a crucial treatment option for high-risk patients who are not suitable for surgery. This minimally invasive approach has demonstrated successful clinical outcomes in patients deemed ineligible for surgical procedures. Patient selection criteria and advancements in operative techniques are critical for achieving successful TAVI outcomes. While the transfemoral approach is the most commonly used method, alternative techniques such as transapical, transaxillary, transcarotid, and transaortic approaches are also available. The Pericapsular Nerve Group Block (PENG) targets the femoral and accessory obturator nerves, providing analgesia to the anterior hip without causing motor block. The Fascia Iliaca Block (FIB), on the other hand, provides broader analgesic coverage by affecting the lateral femoral cutaneous, obturator, and femoral nerves. This study aims to compare PENG block, FIB, and local infiltration anesthesia in TAVI patients regarding sedation requirements during the procedure and postoperative analgesia management. Additionally, pain scores, motor block presence, opioid consumption, and side effects will be assessed. The study seeks to identify optimal strategies to enhance patient comfort and safety during TAVI procedures.

Participants needed: 60
Trial details
Age: 18-85Biological sex: AllType: InterventionalSponsor: Medipol UniversityUpdated: Dec 2, 2025Locations: 1
Eligibility criteria

Patients scheduled for TAVİ [+2]

History of bleeding diathesis. [+7]

Status: Recruiting

Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery

To examine the impact of various administration routes of dexmedetomidine in conjunction with ultrasound-guided fascia iliaca block (FIB) on emergence agitation (EA) during the postoperative recovery period after hip replacement surgery.

Participants needed: 207
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: Qianfoshan HospitalUpdated: Sep 26, 2024Locations: 1
Eligibility criteria

age between 18 and 65 years, with no restriction on gender [+5]

patients allergic to or with contraindications to ropivacaine or dexmedetomidine [+6]